Degraders in epigenetic therapy : PROTACs and beyond
© The author(s)..
Epigenetics refers to the reversible process through which changes in gene expression occur without changing the nucleotide sequence of DNA. The process is currently gaining prominence as a pivotal objective in the treatment of cancers and other ailments. Numerous drugs that target epigenetic mechanisms have obtained approval from the Food and Drug Administration (FDA) for the therapeutic intervention of diverse diseases; many have drawbacks, such as limited applicability, toxicity, and resistance. Since the discovery of the first proteolysis-targeting chimeras (PROTACs) in 2001, studies on targeted protein degradation (TPD)-encompassing PROTACs, molecular glue (MG), hydrophobic tagging (HyT), degradation TAG (dTAG), Trim-Away, a specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPER), antibody-PROTACs (Ab-PROTACs), and other lysosome-based strategies-have achieved remarkable progress. In this review, we comprehensively highlight the small-molecule degraders beyond PROTACs that could achieve the degradation of epigenetic proteins (including bromodomain-containing protein-related targets, histone acetylation/deacetylation-related targets, histone methylation/demethylation related targets, and other epigenetic targets) via proteasomal or lysosomal pathways. The present difficulties and forthcoming prospects in this domain are also deliberated upon, which may be valuable for medicinal chemists when developing more potent, selective, and drug-like epigenetic drugs for clinical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Theranostics - 14(2024), 4 vom: 19., Seite 1464-1499 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dai, Xing-Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug design |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.7150/thno.92526 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368798313 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368798313 | ||
| 003 | DE-627 | ||
| 005 | 20240229155508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7150/thno.92526 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM368798313 | ||
| 035 | |a (NLM)38389844 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dai, Xing-Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Degraders in epigenetic therapy |b PROTACs and beyond |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The author(s). | ||
| 520 | |a Epigenetics refers to the reversible process through which changes in gene expression occur without changing the nucleotide sequence of DNA. The process is currently gaining prominence as a pivotal objective in the treatment of cancers and other ailments. Numerous drugs that target epigenetic mechanisms have obtained approval from the Food and Drug Administration (FDA) for the therapeutic intervention of diverse diseases; many have drawbacks, such as limited applicability, toxicity, and resistance. Since the discovery of the first proteolysis-targeting chimeras (PROTACs) in 2001, studies on targeted protein degradation (TPD)-encompassing PROTACs, molecular glue (MG), hydrophobic tagging (HyT), degradation TAG (dTAG), Trim-Away, a specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPER), antibody-PROTACs (Ab-PROTACs), and other lysosome-based strategies-have achieved remarkable progress. In this review, we comprehensively highlight the small-molecule degraders beyond PROTACs that could achieve the degradation of epigenetic proteins (including bromodomain-containing protein-related targets, histone acetylation/deacetylation-related targets, histone methylation/demethylation related targets, and other epigenetic targets) via proteasomal or lysosomal pathways. The present difficulties and forthcoming prospects in this domain are also deliberated upon, which may be valuable for medicinal chemists when developing more potent, selective, and drug-like epigenetic drugs for clinical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PROTACs, epigenetics, anti-cancer | |
| 650 | 4 | |a drug design | |
| 650 | 4 | |a protein degrader | |
| 650 | 7 | |a Histones |2 NLM | |
| 700 | 1 | |a Ji, Shi-Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Meng-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Gao-Zhi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hui-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shao-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Herdewijn, Piet |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yi-Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Sai-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiao-Bing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Theranostics |d 2011 |g 14(2024), 4 vom: 19., Seite 1464-1499 |w (DE-627)NLM20717458X |x 1838-7640 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:4 |g day:19 |g pages:1464-1499 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7150/thno.92526 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 4 |b 19 |h 1464-1499 | ||